Clinical trials: Healthy Volunteers Overweight
Obesity and Overweight
A First-in-human Study of HCR-188 in Overweight or Obese Otherwise Healthy Volunteers Without Type 2 Diabetes
This is a first-in-human study evaluating the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of single and multiple doses of HCR-188 administered as subcutaneous injection(s).
- Trial name
- NCT06845943
- Testing
- HCR-188
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Helicore Biopharma, Inc.
Part A: Healthy Part B: Overweight or Obesity
A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and…
- Trial name
- NCT07160400
- Testing
- IBI3032 tablets
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Healthy, Obesity
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight
Part 1: To investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3034701 in Japanese male and female participants with body mass index (BMI) ≥27.0 kg/m² or more following subcutaneous…
- Trial name
- NCT07693231
- Testing
- BI 3034701
- Where
- 3 sites in Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects
This study is designed to compare the pharmacokinetics of three different formulations of Pf-04937319
- Trial name
- NCT01513928
- Testing
- Pf-04937319
- Where
- Singapore
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overweight
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity
The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity.
- Trial name
- NCT07476118
- Testing
- Brenipatide
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity & Overweight, Type 2 Diabetes
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults
- Trial name
- NCT07539415
- Testing
- DWRX5003, DWC202502, DWC202503
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Overweight or Obesity
A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
This Phase I, active-controlled, randomised trial will be conducted in 2 parts. Part I aims to confirm the PD equivalence of EMP22 and Xenical® based on percent fecal fat excretion at steady state.
- Trial name
- NCT06013163
- Testing
- Xenical® vs EMP 22, EMP 22 vs Xenical®, EMP 16 vs Xenical®
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Empros Pharma AB
Healthy Volunteer
A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives
This Study of ABBV-295 subcutaneous injections will assess pharmacokinetics and adverse events in healthy adult women participants with overweight or obesity taking oral contraceptives.
- Trial name
- NCT07414784
- Testing
- ABBV-295, Levonorgestrel/Ethinyl Estradiol
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- AbbVie
Hypothalamic Obesity, Prader-Willi Syndrome
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with MC4R Pathway Impairment
- Conditions
- Hypothalamic Obesity, Prader-Willi Syndrome, PWS
- Trial name
- NCT06239116
- Testing
- Part C: RM-718, Part D: RM-718
- Where
- 7 sites in United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity, Overweight
A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight
The primary objective of this study is to evaluate the effect of a meal and evening dosing on the pharmacokinetics (PK) of KAI 7535 in healthy participants living with obesity or overweight.
- Trial name
- NCT07294898
- Testing
- KAI-7535
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Kailera
Healthy
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity
This study is open to healthy people and people with overweight or obesity. It has 2 parts. Part A is open to healthy men between 18 and 55 years of age.
- Trial name
- NCT06352437
- Testing
- BI 3034701
- Where
- Germany
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Participants
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol…
- Trial name
- NCT07013643
- Testing
- AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP)
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese
A study in healthy male and female participants of non-childbearing potential who are overweight or obese.
- Trial name
- NCT05511025
- Testing
- AZD6234, Acetaminophen
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers, Overweight
A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide
The study will look at how two different versions of semaglutide reach and stay in the blood after injection. The study aims to show similar levels of semaglutide in the blood when using the different versions.
- Conditions
- Healthy Volunteers, Overweight, Obesity
- Trial name
- NCT04228354
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight and Obese Volunteers
A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants
To investigate the safety and tolerability after single and multiple ascending doses of MDR-001 Tablets administered orally in healthy participants and obese/ overweight participants.
- Trial name
- NCT06778850
- Testing
- MDR-001, palcebo
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- MindRank AI Ltd
Healthy
A Study of LY3463251 in Healthy Participants
The purpose of this study is to evaluate the safety and tolerability (side effects) of single (Part A) and multiple (Part B) doses of the study drug when it is administered subcutaneously (under the skin) into the abdomen.
- Trial name
- NCT03764774
- Testing
- LY3463251
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteer
A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)
Ertugliflozin (PF-04971729, MK-8835) is under development for the treatment of Type 2 Diabetes. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral…
- Trial name
- NCT01018823
- Testing
- Ertugliflozin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110.
- Trial name
- NCT01146327
- Testing
- PF-04620110
- Where
- 2 sites in Belgium, Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects
MOD-6031 is a long-acting reversibly PEGylated oxyntomodulin (OXM) therapeutic. The active moiety is a gastrointestinal neuropeptide with a sequence identical to endogenous human OXM and is an agonist for both glucagon-like…
- Trial name
- NCT02692781
- Testing
- MOD-6031
- Where
- Israel
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- OPKO Health, Inc.
Obesity &Amp; Overweight
Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity
Study to assess the safety, pharmacokinetics (the amount of study drug or any of its breakdown products in your body) and pharmacodynamics (how the study drug affects your body) of RN3161 alone (healthy volunteers) and RN3161…
- Trial name
- NCT07245771
- Testing
- RN3161, Tirzepatide
- Where
- Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Ikaria Bioscience Pty Ltd